GlassScriptPhysician profile
Hetal Vachhani
NPI 1295945764
$159.28
in general payments reported to CMS, 2019-2025
7 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $21.43 · 2023: $51.51 · 2024: $43.77 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.28 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.28 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $46.44 | 2021-2023 | Trodelvy |
| Boston Scientific Corporation | $38.93 | 2022-2024 | Compliance Endokit |
| Pfizer INC. | $30.65 | 2025 | |
| Daiichi Sankyo INC. | $16.99 | 2023 | Enhertu |
| Conmed Corporation | $15.15 | 2024 | Conmed Generators, Conmed Dilation, Conmed Biliary |
| Merit Medical Systems INC | $11.12 | 2024 | Endomaxx Stent and Delivery System, Alimaxx-Esophageal Stent/Delivery System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Vachhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.